XML 40 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Restructuring Expenses
 12 Months Ended
Dec. 31, 2021
Restructuring and Related Activities [Abstract]  
Restructuring Expenses Restructuring Expenses
During 2020, the Company announced a company-wide organizational realignment initiative in order to more effectively align its organizational infrastructure and operations with the industry vision of the Autonomous Pharmacy. During the second quarter of 2020, the Company also initiated a restructuring plan to help mitigate the adverse impact of the COVID-19 pandemic on its business and financial results. During the year ended December 31, 2020, the Company incurred $10.0 million of employee severance costs and related expenses.
During the first quarter of 2021, the Company continued its organizational realignment initiative, incurring $2.0 million of employee severance costs and related expenses. As of December 31, 2021, there was no unpaid balance related to this realignment initiative.
The following table summarizes the total restructuring expenses recognized in the Company’s Consolidated Statements of Operations for the years ended December 31, 2021, 2020, and 2019:
Year Ended December 31,
202120202019
(In thousands)
Cost of product and service revenues$389 $2,564 $— 
Research and development105 3,716 — 
Selling, general, and administrative1,526 3,681 — 
Total restructuring expenses$2,020 $9,961 $—